UPC invalidates Enanta’s Paxlovid patent across 18 states—but its reasoning is not public

The story

The Unified Patent Court has invalidated an Enanta Pharmaceuticals patent asserted against Pfizer’s COVID-19 treatment Paxlovid, delivering a single judgment with consequences across 18 participating European Union states. Enanta disclosed the October 29 outcome in a filing with the US Securities and Exchange Commission: the court concluded that European Patent EP 4 051 265 was invalid and that Enanta’s infringement action was unfounded. Pfizer had denied infringement and counterclaimed for revocation.

That result is consequential, but the available evidence imposes an important limit on what can be reported. The UPC judgment and its reasoning were not public in the court register when this article was prepared. Enanta’s filing states the outcome but does not identify the ground on which the patent fell. Independent legal reporting by Law360 confirms Pfizer’s victory, while the patent-litigation publication p05 likewise reports that the written decision is unavailable. It would therefore be wrong to attribute the decision to lack of novelty, inventive step, insufficiency or any other specific doctrine until the judgment appears.

Enanta brought the UPC action in August 2025, shortly after the European patent was granted. According to its original securities filing, the company alleged that the nirmatrelvir component of Paxlovid infringed the patent in all 18 countries then participating in the UPC system. The court held an oral hearing on September 29, 2026. The dispute thus moved from filing to a cross-border validity result in little more than a year—one of the practical changes the UPC was designed to produce.

The patent is titled “Functionalized peptides having two pyrrolidine rings as anti-coronavirus agents.” Its public bibliographic record lists a July 19, 2021 filing date and claims priority from July 20, 2020. The specification describes compounds intended to inhibit coronavirus 3C-like protease, or 3CLpro, an enzyme needed for viral polyprotein processing. Nirmatrelvir, the antiviral component paired with ritonavir in Paxlovid, also targets that protease. Those shared technical coordinates explain the litigation; they do not, by themselves, establish that every claim covered Pfizer’s molecule or that the patent was valid.

Revocation changes the commercial equation. A patent held invalid cannot support an injunction or damages for infringement in the UPC territory covered by the action. But the ruling is narrower than a declaration about the entire Paxlovid product or Enanta’s full research portfolio. It does not establish that Pfizer owns Enanta’s work, that all related patents are invalid, or that national and foreign family members necessarily rise or fall with EP 4 051 265. Claim language, prior art, procedural posture and applicable law can differ from one right and one forum to another.

A parallel validity route remains active. European Patent Office records show that Pfizer filed an opposition to EP 4 051 265 on May 6, 2026. EPO opposition and UPC revocation are separate proceedings, and Europe’s post-grant system permits them to run in parallel. The EPO’s technical and legal analysis may therefore provide another public account of the patent’s strengths and weaknesses even after the UPC result. How the EPO responds to the central court’s judgment—and whether either proceeding pauses or narrows the other—will matter for portfolio strategy.

The European defeat also follows a separate US setback. Enanta asserted US Patent 11,358,953 against Pfizer in Massachusetts; the district court held the asserted claims invalid in 2024, and the US Court of Appeals for the Federal Circuit affirmed that judgment on June 23, 2026. The sequence is commercially relevant, but it is not proof that the UPC adopted the US court’s reasoning. European and US patents can contain different claims, and their validity standards and procedural rules are not interchangeable.

INNOVOX analysis: the clearest lesson is about the new geography of patent risk. Before the UPC, a life-sciences challenger often had to contest the same European patent country by country. A central UPC counterclaim can now erase enforcement leverage across participating states in one proceeding. That efficiency benefits companies seeking market certainty, but it also magnifies the cost of weak drafting, incomplete prior-art analysis or an overextended infringement theory. A patent owner can lose a multinational position almost as quickly as it can seek a multinational injunction.

Transparency is the immediate issue to watch. A bare result can move licensing expectations and investor assumptions, yet it cannot reliably guide inventors or patent drafters. The next meaningful evidence will be the written judgment, any notice of appeal and the developing EPO opposition file. Until those materials are public, the responsible conclusion is deliberately limited: Enanta lost this UPC case, EP 4 051 265 was held invalid across the covered territory, and the wider significance of the ruling remains unresolved.

INNOVOX analysis

The case shows the concentrated power—and the information risk—of Europe’s new patent system. One central revocation outcome can remove leverage across a large market, but companies, researchers and investors cannot responsibly assess its wider precedential value until the court publishes the reasoning and identifies which claims and validity arguments carried the decision.

What to watch

Watch for publication of the UPC judgment, any Enanta appeal, the EPO opposition record and the treatment of other members of Enanta’s coronavirus-protease patent family. Those documents will show whether the setback turns on prior art, inventive step, sufficiency, claim scope or another ground—and whether it reaches beyond this patent and this product.